2024
Safety of the Seasonal Influenza Vaccine in 2 Successive Pregnancies
Getahun D, Liu I, Sy L, Glanz J, Zerbo O, Vazquez-Benitez G, Nelson J, Williams J, Hambidge S, McLean H, Irving S, Weintraub E, Qian L. Safety of the Seasonal Influenza Vaccine in 2 Successive Pregnancies. JAMA Network Open 2024, 7: e2434857. PMID: 39298167, PMCID: PMC11413712, DOI: 10.1001/jamanetworkopen.2024.34857.Peer-Reviewed Original ResearchConceptsAdverse perinatal outcomesPreterm premature rupture of membranesPremature rupture of membranesPreterm premature ruptureRupture of membranesRisk of preeclampsiaSeasonal influenza vaccineInfluenza vaccineAssociated with increased riskInterpregnancy intervalPerinatal outcomesVaccine typesPlacental abruptionPreterm birthInfluenza seasonAssociated with increased risk of preeclampsiaCohort studyRisk of adverse perinatal outcomesAssociated with increased risk of adverse perinatal outcomesSingleton live birth pregnanciesRelative riskLive-birth pregnanciesGestational age birthsRetrospective cohort studyAdjusted relative risksReactive axillary lymph nodes after COVID-19 mRNA vaccination: comparison of mRNA vs. attenuated whole-virus vaccines
Adin M, Isufi E, Wu J, Pang Y, Nguyen D, Has D, Caner C, Aboueldaha N, Mossa-Basha M, Pucar D. Reactive axillary lymph nodes after COVID-19 mRNA vaccination: comparison of mRNA vs. attenuated whole-virus vaccines. Nuclear Medicine Communications 2024, 45: 474-480. PMID: 38465449, DOI: 10.1097/mnm.0000000000001833.Peer-Reviewed Original ResearchAxillary lymph nodesWhole virus vaccineLymph nodesMRNA vaccinesNatural courseValue of clinical parametersCOVID-19 mRNA vaccinesPredictive value of clinical parametersDose of vaccine administrationPET-CT studiesCohort of oncology patientsDeauville criteriaPET criteriaClinical parametersYounger patientsSingle doseModerna recipientsJ&J vaccinePET-positiveMultivariate analysisVaccine typesOncology patientsPredictive valueVaccine administrationModerna vaccineFactors influencing adverse events following COVID-19 vaccination
Villanueva P, McDonald E, Croda J, Croda M, Dalcolmo M, dos Santos G, Jardim B, Lacerda M, Lynn D, Marshall H, Oliveira R, Rocha J, Sawka A, Val F, Pittet L, Messina N, Curtis N. Factors influencing adverse events following COVID-19 vaccination. Human Vaccines & Immunotherapeutics 2024, 20: 2323853. PMID: 38445666, PMCID: PMC10936640, DOI: 10.1080/21645515.2024.2323853.Peer-Reviewed Original ResearchConceptsVaccine typesSystemic reactionsIncidence of AEFIAdverse eventsVaccine doseIncidence of adverse eventsCovid-19 specific vaccineCOVID-19 vaccineNested cohort studyIgG antibody responsesRisk of AEFICOVID-19 vaccine typesChAdOx1 recipientsBNT162b2 recipientsCohort studyPfizer-BioNTechCoronaVac vaccineAntibody responseChAdOx1Oxford-AstraZenecaCoronaVacBNT162b2Local reactionsDoseDevelopment of COVID-19 vaccines
2023
Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations
Akhtar M, Islam M, Khaton F, Soltana U, Jafrin S, Rahman S, Tauheed I, Ahmed T, Khan I, Akter A, Khan Z, Islam M, Khanam F, Biswas P, Ahmmed F, Ahmed S, Rashid M, Hossain M, Alam A, Alamgir A, Rahman M, Ryan E, Harris J, LaRocque R, Flora M, Chowdhury F, Khan A, Banu S, Shirin T, Bhuiyan T, Qadri F. Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations. Frontiers In Immunology 2023, 14: 1309997. PMID: 38173725, PMCID: PMC10763240, DOI: 10.3389/fimmu.2023.1309997.Peer-Reviewed Original ResearchConceptsFuture vaccination strategiesIgG responsesVaccination strategiesVaccine typesImmunological toleranceImmune responseMRNA dosesSpecific IgG antibody responseIgG subclass analysisRobust IgG responseChAdOx1 nCoV-19IgG antibody responsePrimary IgG responseSARS-CoV-2 variantsHumoral immune responseMRNA vaccine dosesCOVID-19 vaccinationNumber of dosesSARS-CoV-2 spike receptorBooster dosesBooster vaccinationIgG4 levelsIgG4 responsesMRNA vaccinationIgG levels
2022
Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELY
Hulme WJ, Williamson EJ, Green ACA, Bhaskaran K, McDonald HI, Rentsch CT, Schultze A, Tazare J, Curtis HJ, Walker AJ, Tomlinson LA, Palmer T, Horne EMF, MacKenna B, Morton CE, Mehrkar A, Morley J, Fisher L, Bacon SCJ, Evans D, Inglesby P, Hickman G, Davy S, Ward T, Croker R, Eggo RM, Wong AYS, Mathur R, Wing K, Forbes H, Grint DJ, Douglas IJ, Evans SJW, Smeeth L, Bates C, Cockburn J, Parry J, Hester F, Harper S, Sterne JAC, Hernán MA, Goldacre B. Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELY. The BMJ 2022, 378: e068946. PMID: 35858680, PMCID: PMC9295078, DOI: 10.1136/bmj-2021-068946.Peer-Reviewed Original ResearchConceptsCovid-19 related hospital admissionCOVID-19 vaccineCOVID-19 diseaseRelated hospital admissionsCumulative incidenceHospital admissionSocial care workersCare workersCohort studyHealthcare workersPositive SARS-CoV-2 testBNT162b2 COVID-19 vaccineChAdOx1 COVID-19 vaccineSARS-CoV-2 positive testSARS-CoV-2 infectionSARS-CoV-2 alpha variantSARS-CoV-2 testCOVID-19First vaccine doseComparative effectiveness trialFirst dose vaccinationBNT162b2 mRNAHospital attendanceVaccine doseVaccine typesChanges Over Time in COVID-19 Incidence, Vaccinations, Serum Spike IgG, and Viral Neutralizing Potential Among Individuals From a North American Gaming Venue
Wisnewski AV, Cantley L, Luna J, Liu J, Smith RF, Hager K, Redlich CA. Changes Over Time in COVID-19 Incidence, Vaccinations, Serum Spike IgG, and Viral Neutralizing Potential Among Individuals From a North American Gaming Venue. Journal Of Occupational And Environmental Medicine 2022, 64: 788-796. PMID: 36054278, PMCID: PMC9426317, DOI: 10.1097/jom.0000000000002617.Peer-Reviewed Original ResearchConceptsOccupational risk factorsCOVID-19 historyRisk factorsAnti-spike IgG levelsIndividual humoral responsesSerum antiviral antibodiesCOVID-19 vaccinationEnzyme-linked immunosorbent assayCOVID-19 ratesCOVID-19 incidenceSpike IgGVaccine nonrespondersVaccination statusIgG levelsVaccine responsesVaccine typesAntiviral antibodiesHumoral responseCOVID-19 casesVaccine availabilityImmunosorbent assayVaccinationInfectionMonthsParticipants
2021
Resource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach
Kim D, Pekgün P, Yildirim İ, Keskinocak P. Resource allocation for different types of vaccines against COVID-19: Tradeoffs and synergies between efficacy and reach. Vaccine 2021, 39: 6876-6882. PMID: 34688498, PMCID: PMC8520874, DOI: 10.1016/j.vaccine.2021.10.025.Peer-Reviewed Original ResearchConceptsInfection attack rateVaccine typesDifferent vaccine typesResource-limited countriesHigh-efficacy vaccinesDifferent study parametersVaccine shortageEfficacy vaccineHealth outcomesLife-saving vaccinesVaccineVaccine distributionLow efficacyAttack rateStudy parametersEfficacyHigh efficacyCOVID-19COVID-19 pandemicDeceased (SIRD) modelDifferent resource allocation decisionsLimited accessPerioperative Coronavirus Vaccination—Timing and Implications: A Guidance Document
Merritt-Genore H, Moosdorf R, Gillaspie E, Lother S, Engelman D, Ahmed S, Baciewicz FA, Grant MC, Milewski R, Cawcutt K, Hayanga JA, Chatterjee S, Arora RC, Care S. Perioperative Coronavirus Vaccination—Timing and Implications: A Guidance Document. The Annals Of Thoracic Surgery 2021, 112: 1707-1715. PMID: 34370980, PMCID: PMC8349423, DOI: 10.1016/j.athoracsur.2021.07.016.Peer-Reviewed Original ResearchBacterial Spectrum of Spontaneously Ruptured Otitis Media in a 7-Year, Longitudinal, Multicenter, Epidemiological Cross-Sectional Study in Germany
Imöhl M, Perniciaro S, Busse A, van der Linden M. Bacterial Spectrum of Spontaneously Ruptured Otitis Media in a 7-Year, Longitudinal, Multicenter, Epidemiological Cross-Sectional Study in Germany. Frontiers In Medicine 2021, 8: 675225. PMID: 34095179, PMCID: PMC8172772, DOI: 10.3389/fmed.2021.675225.Peer-Reviewed Original ResearchMiddle ear fluidNasopharyngeal swabsMEF samplesOtitis mediaAcute otitis media casesEpidemiological cross-sectional studyPCV7-vaccinated childrenRoutine pneumococcal vaccinationChildren 2 monthsNon-vaccinated childrenOtitis media casesCross-sectional studyNPS samplesOverall case numbersAOM patientsMEF isolatesPCV13 serotypesPCV7 serotypesPneumococcal vaccinationVaccination statusVaccine typesSerotype distributionBacterial etiologyDisease burdenEar fluid
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply